Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Overview

This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

Full Title of Study: “A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton’s Tyrosine Kinase Inhibitor (BTKi)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2020

Interventions

  • Drug: Duvelisib
    • Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles

Arms, Groups and Cohorts

  • Experimental: Duvelisib
    • Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles

Clinical Trial Outcome Measures

Primary Measures

  • Overall Response Rate (ORR)
    • Time Frame: From start of treatment to first documented response, 2 cycles (58 days)

Secondary Measures

  • Treatment-Emergent adverse events (TEAEs) and changes in laboratory values
    • Time Frame: From start of treatment to end of treatment plus 30 days; 7 months
  • Duration of response (DOR), defined as the time from the first documentation of response to the first documentation of PD or death due to any cause
    • Time Frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months
  • Progression-free survival (PFS), defined as the time from the first dose of study treatment to the first documentation of PD or death from any cause
    • Time Frame: Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months
  • Disease control rate (DCR), defined as CR/CRi + PR/PRwL + stable disease (SD) ≥ 8 weeks
    • Time Frame: Greater than or equal to 8 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. ≥ 18 years of age. 2. Diagnosis of CLL or SLL. 3. Received at least one prior anti-cancer therapy for CLL or SLL. 4. Previous exposure to BTKi and meet at least one of the criteria below: 1. Progressive disease (PD) while receiving or within 6 months after completing BTKi therapy. 2. Discontinued a BTKi therapy due to BTKi treatment- related intolerance. 5. Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension. 6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 7. Resolution of toxicities due to prior BTKi therapy to acceptable level. 8. Willingness of male and female patients to use medically acceptable methods of birth control. 9. Willing and able to participate in all required study evaluations and procedures. Exclusion Criteria:

1. Richter's transformation or prolymphocytic leukemia 2. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia 3. Received prior transplant 4. Experienced PD or serious adverse events on a prior phosphoinositide-3-kinase (PI3K) inhibitor 5. Known central nervous system involvement by CLL/SLL

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • SecuraBio
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.